The Medicines Company to Host Conference Call and Webcast at Upcoming American College of Cardiology’s 66th Annual Scientific Sessions

PARSIPPANY, N.J.–(BUSINESS WIRE)– The Medicines
Company (NASDAQ:MDCO) will host a conference call and webcast on
Friday, March 17, 2017, at 3:30 p.m., Eastern Time, to review data from
the ORION-1 Phase II study of inclisiran, the Company’s PCSK9 synthesis
inhibitor. During the call, the Company’s management and inclisiran
product teams, as well as members of its distinguished advisory board,
will review full safety and efficacy data from ORION-1, with six to nine
month follow-up for all patients in the study, which will have been
presented earlier in the day in the “Late-Breaking Clinical Trials –
Featured Clinical Research 1” session at the American College of
Cardiology’s 66^th Annual Scientific Session.

The conference call may be accessed as follows:

U.S./Canada: (877) 359-9508
International: (224) 357-2393
Conference
ID: 60380330

The live webcast may be accessed in the Investors section of The
Medicines Company website.

A taped replay of the conference call will be available for
approximately one week. The replay may be accessed as follows:

U.S./Canada: (855) 859-2056
International: (404) 537-3406
Conference
ID: 60380330

A replay of the webcast will also be available.

About The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an
overriding purpose – to save lives, alleviate suffering and contribute
to the economics of healthcare. The Company’s mission is to create
transformational solutions to address the most pressing healthcare needs
facing patients, physicians and providers in three critical therapeutic
areas: serious infectious disease care, cardiovascular care and surgery
and perioperative care. The Company is headquartered in Parsippany, New
Jersey, with global innovation centers in California and Switzerland.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170306005437/en/